PDCD1 and B-cell chronic lymphocytic leukemia: Thus, our discovery points toward combining ibrutinib with PD-1 inhibitors being an approach that ought to be pursued in aiming to counteract prospective immunologic escape as well as resistance patterns in CLL patients unresponsive to monotherapy with BTK inhibitors [27].